A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Inclusion Criteria: * Be of Japanese descent, defined as born in Japan and having Japanese parents and Japanese maternal and paternal grandparents. * Participants must have a documented diagnosis of a form of primary humoral immunodeficiency involving antibody formation and requiring gammaglobulin replacement. The diagnosis must be confirmed by the medical director prior to treatment with IGIV. * Participant is 2 years or older at the time of screening. * Written informed consent is obtained from either the participants or the participants legally authorized representative prior to any study-related procedures and study product administration. * Participant has been receiving a consistent dose of IGIV over a period of at least 3 months prior to screening equivalent to approximately 200-600 mg/kg-body weight (BW) per 3- 4 week period, as according to the product package insert * Participant has a serum trough level of IgG \>= 5 gram per liter (g/L) at screening. * Participant has not had a serious bacterial infection within the 3 months prior to screening. * Participant is willing and able to comply with the requirements of the protocol. Exclusion Criteria: * Participant has a known history of or is positive at screening for one or more of the following: hepatitis B surface antigen (HBsAg), polymerase chain reaction (PCR) for hepatitis C virus (HCV), PCR for human immunodeficiency virus (HIV) Type 1/2. * Abnormal laboratory values at screening meeting any one of the followi…